Introduction {#sec1-1}
============

Parkinson\'s disease (PD) affects 1% of people over the age of 50 years, though unrecognized early symptoms of the disease may be present in as many as 10% of those over 60 years of age.\[[@ref1][@ref2]\] Gender difference exists in the incidence and prevalence of PD, being 1.5-2 times\[[@ref3][@ref4][@ref5][@ref6][@ref7][@ref8]\] higher in men than women. The disease also manifests at a later age in women by a mean of 2.2 years.\[[@ref9]\] Women with PD have better motor scores in Unified Parkinson\'s Disease Rating Scale (UPDRS), but higher prevalence of dyskinesia.\[[@ref10][@ref11]\] These gender differences are attributed to differences in hormonal and life style factors and differences in exposure to risk factors for PD.\[[@ref10]\] Even though the precise nature of the role of estrogen in PD remains unclear, differences in circulating levels of estrogens in men and women could be an important determinant of the differences in clinical manifestations.\[[@ref10]\] When such gender differences exist in the risk of developing PD, severity of motor symptoms and treatment related motor complications, it is essential to examine if gender differences influence selection and outcome of surgical treatment for motor complications of PD, particularly in different ethnic populations.

Deep brain stimulation of the sub thalamic nucleus (STN DBS) has emerged as an effective treatment for the management of motor fluctuations and dyskinesias that are not optimally controlled with medications.\[[@ref12][@ref13]\] Hariz *et al*.,\[[@ref14]\] in their surgical series of 38 patients who underwent stereotactic neurosurgery concluded that women are probably selected less frequently and later than necessary for surgical treatment. These sort of gender-based differences are more likely to occur in resource-poor countries like India, where the enormous cost of surgical treatment of PD is often met by patients themselves. We undertook this study to address the gender differences in the pre-operative characteristics and post-operative outcome among 51 consecutive Indian patients who underwent STN DBS at our center.

Materials and Methods {#sec1-2}
=====================

Fifty-one consecutive patients who underwent bilateral STN DBS for advanced PD and completed 1-year follow-up participated in the study.

All subjects were assessed using UPDRS I-IV, 1 month before surgery (baseline evaluation) in the *off*-medication and *on*-medication conditions. All patients underwent bilateral stereotactic implantation of quadripolar DBS electrodes (Medtronic, MN, USA) in one session according to the standard protocol described in our earlier study.\[[@ref13]\] All patients were evaluated 1 year after surgery in "*on*-stimulation, *off*-medication" state. UPDRS III was rated (except rigidity) on videos by another blinded movement disorder specialist who was not part of the surgical team. Scores for rigidity were taken from the open-label UPDRS III scores rated as part of yearly follow-up. The levodopa equivalent daily dosage (LEDD) was calculated for all patients.\[[@ref15]\] All the patients also underwent mini mental status examination (MMSE), Addenbrooke\'s cognitive examination (ACE)\[[@ref16]\] and quality of life (QOL) assessment using Parkinson\'s Disease Quality of Life (PDQL)\[[@ref17]\] at baseline and 1 year follow-up.

Statistical analysis {#sec2-1}
--------------------

We analyzed the gender based differences for the pre-operative disease-related characteristics and the outcomes of STN DBS. The post-operative outcome was measured from the assessment in "*on*-stimulation, *off*-medication" state. The outcome of DBS was assessed as the change of each score from the baseline to the post-operative state in both genders. To compare data before and after surgery and between genders, a repeated measures analysis of variance (ANOVA) was done with factors gender (independent measure) and 'DBS outcome' (repeated measures). Mann-Whitney test was used to compare percentage reductions for each item between the two genders. A probability value of *P* \< 0.05 was considered significant.

Results {#sec1-3}
=======

Baseline characteristics {#sec2-2}
------------------------

There were 32 men and 19 women. Baseline evaluation \[[Table 1](#T1){ref-type="table"}\] revealed no gender differences in the age at onset, duration of disease and severity of the motor symptoms of the disease assessed by Hoehn and Yahr staging. The activities of daily living (ADL) scores (UPDRS II), were similar in OFF, though there was a trend for it to be worse in women in ON (*P* = 0.05). No significant differences were noted in the UPDRS III motor scores, even though women showed a trend towards having worse bradykinesia (*P* = 0.05) and axial motor (*P* = 0.07) scores compared to men during ON. Women were on lesser LEDD than men (*P* = 0.03). The dyskinesia and fluctuations scores (UPDRS IV) were also similar between the genders. PDQL showed significantly worse emotional sub scores in women (*P* = 0.03). Baseline neuropsychological evaluation showed no difference in ACE and MMSE scores. Depression at baseline was worse in women (*P* = 0.03).

###### 

Characteristics of the study population at baseline
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Assessment 1 year after surgery {#sec2-3}
-------------------------------

The 1-year post-operative assessment \[[Table 2](#T2){ref-type="table"}\] showed significant improvement in UPDRS I-IV in both genders. The analysis of UPDRS III scores did not show any difference in the degree of improvement of any of the cardinal motor manifestations of PD \[[Table 2](#T2){ref-type="table"}\]. Even though both genders achieved significant reduction of the LEDD at the end of 1 year (*P* \< 0.001), women achieved lesser reduction of LEDD (*P* = 0.022). All domains of PDQL improved with surgery without any gender differences in the degree of improvement \[[Table 2](#T2){ref-type="table"}\]. MMSE and ACE scores also showed no gender differences. Depression improved in both genders (*P* = 0.016) and equally. The electrical stimulation parameters also did not differ significantly between men and women (data not shown).

###### 

Comparison of the outcome of STN DBS among men and women 1 year after surgery
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Discussion {#sec1-4}
==========

In our surgical cohort of 51 patients who underwent bilateral STN DBS for advanced PD, we found no gender differences in the age of onset, duration, and severity of motor symptoms or levodopa-induced dyskinesia before surgery. Nevertheless, women were on lower doses of dopaminergic medications and showed a trend toward worse control of bradykinesia and poorer functioning in activities of daily living. They were more depressed compared to men. Despite these differences, motor symptoms, ADL, depression, and QOL improved equally well in women as in men following STN DBS. The only post-operative gender difference was that women achieved lesser reduction of dopaminergic medications.

Contrary to the observation by Hariz *et al*.,\[[@ref14]\] we found that women undergoing STN DBS for advanced PD are selected for the procedure at similar severity and duration of motor symptoms as men, indicating that women in our study received an equal opportunity for STN DBS. The surgical cohort in that study was heterogeneous, consisting of patients undergoing not only DBS, but ablative procedures like pallidotomy and thalamotomy also. A more recent study by Accolla *et al*.,\[[@ref18]\] on patients undergoing DBS found no such differences; their results were similar to our findings. Our results suggest that only financial limitations and not gender based discrimination act as constraints for women with PD to undergo DBS. In the pre-operative assessments, we did not find worse dyskinesias in our female patients, probably due to the lower dose of dopaminergic medications taken by them. This difference in dosage of dopaminergic medications prescribed to women was the result of an intentional reduction in the dosage of medications aimed at the control of troublesome dyskinesia in women. This could explain the equal severity of dyskinesias between the genders, even though women are reported to have more dyskinesia.\[[@ref10][@ref11]\] This dose restriction may also explain the poorer control of bradykinesia and axial signs in ON and the impairment of ADL in women. The reduction in LEDD after surgery was also lesser in women probably because women were already receiving a lower dose prior to surgery. The policy of drug reduction after STN DBS followed at our center aims only to reduce dyskinesias.

The women subjects in our cohort at baseline evaluation were more depressed and had worse emotional score for QOL. Biological factors contribute to worse depression in women, and depression is more common in women with PD,\[[@ref19][@ref20]\] though this has not been a consistent observation.\[[@ref21]\] The prevalence of depression in the general population is also higher in women.\[[@ref19]\] The poorer functioning in activities of daily living even in ON could also have contributed to the poorer emotional state of women in QOL scores. Nevertheless, gender difference in depression disappeared at 1 year of follow-up.

We found that STN DBS resulted in excellent improvement in UPDRS motor scores, fluctuations, dyskinesias, activities of daily living and all domains of quality life irrespective of gender. Romito *et al*.\[[@ref22]\] found slightly worse lower limb akinesia and gait scores in women at 1 year follow-up, but the difference was not seen on subsequent yearly follow-up evaluations. Accolla *et al*.\[[@ref18]\] found that bradykinesia responded poorly in women at baseline as in our study, though a trend for better improvement in ADL was also found after DBS. However, in the present study, the ADL improved to a similar degree in both genders.

The relatively short duration of follow-up (1 year) is a limitation of our study. Moreover, the group of patients that are ultimately candidates for DBS for PD is highly selected, and may not be the ideal one to study the gender differences and to answer the question whether women get an equal opportunity as men to undergo DBS in resource poor countries. Ideally, a prospective study on a cohort of patients with PD being referred for consideration of DBS may be required to address these issues. However, to the best of our knowledge, this is the first attempt to analyze gender differences in patient selection and outcome of STN DBS from a resource-limited country like India. Apart from those used by earlier investigators,\[[@ref14][@ref18]\] we included additional outcome measures for depression and QOL. In conclusion, we found that women with advanced PD are likely to be maintained on lower doses of dopaminergic medications compared to men with similar duration and severity of motor symptoms, probably as an adjustment for the propensity of women to have more dyskinesia. This may also contribute to more functional impairment and reduced emotional well-being in them. Women respond equally well to STN DBS, with similar improvement of ADL, QOL, and depression and would therefore benefit from early surgical interventions when dyskinesias becomes dose-limiting.
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